

Referral Status:	MRN	:
New referral	Order change	Order Renewal
Preferred clinic:	DAYS IN AIC:	DAYS IN HOME:

Substitution permitted

Phon	e: 1-800-809-1265	Fax: 1-86	6-872-89	20										
	eld® (teplizuma ENT DEMOGRAPHI		) Plan d	of Treat	ment									
Patie	nt Name:					Patie	nt's Phone:							
Date of Birth:					Address:									
Allergies:					City, State, Zip:									
Heigh	nt in inches:	Weight:	LB	3 or	KG	Gender: Allergies: See list NKDA								
	NOSIS: (PLEASE CO				О СОМРІ	LETE I		IG)						
	E10.9 - Type 1 diabetes				tions		Other:							
E10.8 - Type 1 diabetes mellitus with unspecified complications  REQUESTED DOCUMENTATION:  HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE? Yes or No														
	Insurance information	ITATION.		PLEASE ST			DER CHANGE:	DEI ONE: 10	23 01 140					
	H&P including tried and	I failed thera	oies	REQUIRED WASHO FROM PREVIOUS THERAPY:		T								
	Full medication list				VIOUS		Continue current order until insurance approved							
4	Required: Recent CBC	C with diff a	nd LFTs											
HOM	HOME SUPPLY ORDER: *Applicable to all home infusion patients subject to insurance approval													
All sup	oplies for vascular acc	ess line care	, dressing	kit, drug ad	dministratio	on, adv	erse reaction kit, Inf	usion pump,	IV pole, p	ole	clamp etc. v	vill be		
	ICATION ORDERS:													
	Patient may be ineligible		•		•		•			•		U	•	
	patient experiences severe cytokine release syndrome, consider temporarily pausing therapy for 1-2 days and review prescribing information before continuing therapy.  Home Anaphylaxis Kit: Dispense and administer for mild and severe reaction. Applicable to all home infusion patients.													
2 Enin	Home nephrine 1 mg/ml 1 ml	Anaphylaxis	Kit: Disp	ense and ad	iminister to	r mild a	and severe reaction. A	applicable to a	all nome in	itusio	on patients.			
	iephilile i mg/mi i mi ienhydramine 50 mg/ml 2 m	nl vial												
, ,	s, needles and 0.9% Norma													
	ete Home Infusion Physiciar hrine administered IM per w								he event of	an ac	dverse reactior	n/anaph	ıylaxis.	
	OA labeling: Premedication	_					·		rst 5 days of	the	14-day treatm	ent cou	urse	
	selected premedication													
	Diphenhydramine	25mg	50mg				Acetaminophen	325mg	500r	ng	650mg	1	1000mg	
ıv	Methylprednisolone	40mg	125mg				Famotidine	20mg	40m	g	•			
IV	Ondansetron	4mg	8mg				Diphenhydramine	25mg	50m	g				
	Other:					PO	Fexofenadine	60mg	180r	ng				
	DOSAGE:						Cetirizine	10mg						
$\checkmark$	Treatment Day		sage				Loratadine	10mg						
	Day 1		ncg/m2				Other:							
	Day 2		mcg/m2			LAB C	AB ORDERS:  Draw CBC with diff & LFT on infusion days 5 and 8  Other:					d 8		
	Day 3		mcg/m2											
	Day 4		mcg/m2										_	
	Day 5-14	1030	mcg/m2										_	
	NISTRATION:						Physician respons							
	Tzield® 100 mcg/mL di	Per FDA labeling, with AST/ALT > 5x ULN, bilirubin > 3x ULN, or												
infusion over a minimum of 30-minutes followed by a 25mL NS flush.  Administer once daily for 14 consecutive days.  Lymphocyte count <500/mcL lasting one week or longer, patient may be ineligible to receive Tzield®											пау ве			
	-		-	oficalan aba		CDEC	· ·							
	Follow first 5 infusion	15 WILII a 1-11	our post ii	แนรเงเเ งมร	servation.	SPEC	<u>IAL/OTHER LAB OR</u> T	DEKS.						
	<u>DF CARE:</u> AIC		JC and Ho	me with a nu	urea							_		
	*If site of care not indicate											_		
LINE	USE/CARE ORDERS		coordinate	with patien	ıı									
	Start PIV/Access CV													
Flush PIV/Access per PIV/PICC/CVC protocol.								Dispense and Administer as Prescribed						
	CRIBER INFORMAT		•				1							
PRO\	/IDER NAME:						PHONE:							
ADDRESS:						FAX:								
CITY, STATE, ZIP:							NPI:							
PRESCRIBER SIGNATURE: (No stamp signatures)							DATE:							
		( Jea	B. 2.B.10								_,,,_,			

Dispense as written/Brand medically necessary